|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
CA1291706C
(en)
|
1986-04-03 |
1991-11-05 |
Alfred Rudolph |
COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
|
|
CA1290249C
(en)
|
1986-04-09 |
1991-10-08 |
Cetus Corporation |
COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
AU617295B2
(en)
|
1986-11-13 |
1991-11-28 |
Sloan-Kettering Institute For Cancer Research |
Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
AU625807B2
(en)
|
1987-09-22 |
1992-07-16 |
Novartis Vaccines And Diagnostics, Inc. |
Uses of recombinant colony stimulating factor-1
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
US4999339A
(en)
|
1988-03-28 |
1991-03-12 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
|
US5061488A
(en)
|
1988-04-15 |
1991-10-29 |
The United States Of America As Represented Department Of Health & Human Services |
Flavone-8-acetic acid and interleukin-2 for cancer therapy
|
|
US5126129A
(en)
|
1988-05-23 |
1992-06-30 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services |
Cancer therapy using interleukin-2 and flavone compounds
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
WO1992010591A1
(en)
|
1990-12-14 |
1992-06-25 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
US5229109A
(en)
*
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
US5306490A
(en)
|
1992-04-20 |
1994-04-26 |
Medlogic, Inc. |
Methods for retarding blister formation by use of cyanoacrylate adhesives
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
WO1994004196A1
(en)
|
1992-08-14 |
1994-03-03 |
Imperial Cancer Research Technology Limited |
Tumour therapy
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5834441A
(en)
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
EP0756604A1
(en)
|
1994-04-22 |
1997-02-05 |
THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services |
Melanoma antigens
|
|
HUT76369A
(en)
|
1994-07-29 |
1997-08-28 |
Smithkline Beecham Corp |
Novel soluble protein compounds
|
|
DE69534265T2
(de)
|
1994-12-12 |
2006-05-04 |
Beth Israel Deaconess Medical Center, Inc., Boston |
Chimäre zytokine und ihre verwendung
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
WO1996040176A1
(en)
|
1995-06-07 |
1996-12-19 |
Sloan-Kettering Institute For Cancer Research |
Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells
|
|
US5985270A
(en)
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
|
US6406689B1
(en)
|
1995-10-03 |
2002-06-18 |
Frank W. Falkenberg |
Compositions and methods for treatment of tumors and metastatic diseases
|
|
US6045788A
(en)
|
1996-02-28 |
2000-04-04 |
Cornell Research Foundation, Inc. |
Method of stimulation of immune response with low doses of IL-2
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
US6001329A
(en)
|
1996-05-06 |
1999-12-14 |
Uab Research Foundation |
Radiolabeled fusion toxins for cancer therapy
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
ATE550042T1
(de)
|
1997-11-20 |
2012-04-15 |
Vical Inc |
Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
|
|
HUP0100813A3
(en)
|
1998-02-25 |
2003-08-28 |
Lexigen Pharmaceuticals Corp L |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US20030105294A1
(en)
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6620382B1
(en)
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
|
US6168785B1
(en)
|
1998-07-16 |
2001-01-02 |
Institut Pasteur |
Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
|
|
US6013659A
(en)
|
1998-09-04 |
2000-01-11 |
University Of Pittsburgh |
Methods of reducing tumor colony number using novel benzothiazole compounds
|
|
EP1143957A3
(en)
|
1998-12-16 |
2002-02-27 |
Warner-Lambert Company |
Treatment of arthritis with mek inhibitors
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
EP1156823B1
(en)
|
1999-02-12 |
2008-10-29 |
The Scripps Research Institute |
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
|
|
US20020058609A1
(en)
|
1999-02-26 |
2002-05-16 |
Eli Gilboa |
Compositions and methods using complexes of calreticulin and antigenic molecules
|
|
CN1362880A
(zh)
|
1999-04-02 |
2002-08-07 |
布赖汉姆妇女医院 |
免疫调制聚合物
|
|
EP1043025B1
(en)
|
1999-04-08 |
2005-06-01 |
Schering Corporation |
Renal cell carcinoma treatment
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US7312318B2
(en)
*
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
|
MXPA02001417A
(es)
|
1999-08-09 |
2002-08-12 |
Lexigen Pharm Corp |
Complejos multiples de citosina-anticuerpo.
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
ATE305801T1
(de)
|
2000-01-20 |
2005-10-15 |
Univ Zuerich Inst Fuer Medizin |
Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
|
|
WO2001074847A2
(en)
|
2000-03-30 |
2001-10-11 |
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services |
T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
|
|
EP2213743A1
(en)
|
2000-04-12 |
2010-08-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1296714B1
(en)
|
2000-06-22 |
2009-08-26 |
University Of Iowa Research Foundation |
Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
|
|
JP3811775B2
(ja)
|
2000-07-19 |
2006-08-23 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
|
|
WO2004007529A2
(en)
|
2002-07-15 |
2004-01-22 |
The Trustees Of Princeton University |
Iap binding compounds
|
|
WO2002044197A2
(en)
|
2000-12-01 |
2002-06-06 |
Fish Eleanor N |
Cytokine receptor binding peptides
|
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
|
US20040253242A1
(en)
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
|
ATE320450T1
(de)
|
2000-12-05 |
2006-04-15 |
Alexion Pharma Inc |
Rationell entworfene antikörper
|
|
IL140796A0
(en)
|
2001-01-08 |
2002-02-10 |
Hadasit Med Res Service |
An autologous anti-cancer vaccine
|
|
CN100522242C
(zh)
|
2001-02-19 |
2009-08-05 |
默克专利有限公司 |
具有降低的免疫原性的人工蛋白质
|
|
RU2003129528A
(ru)
|
2001-03-07 |
2005-04-10 |
Мерк Патент ГмбХ (DE) |
Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
|
|
EP1383785B1
(en)
|
2001-05-03 |
2011-03-16 |
Merck Patent GmbH |
Recombinant tumor specific antibody and use thereof
|
|
CA2448109A1
(en)
|
2001-05-25 |
2002-12-05 |
Thomas Jefferson University |
Alternative splice forms of proteins as basis for multiple therapeutic modalities
|
|
FR2825279B1
(fr)
|
2001-06-01 |
2005-04-08 |
Molecular Engines Lab |
Medicament utile dans le traitement du cancer
|
|
WO2003015697A2
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
US20060084123A1
(en)
|
2001-12-13 |
2006-04-20 |
Harris Adrian L |
MN and hypoxia
|
|
PT1478648E
(pt)
|
2002-02-01 |
2014-07-15 |
Ariad Pharma Inc |
Compostos contendo fósforo e suas utilizações
|
|
CN1653059A
(zh)
|
2002-03-08 |
2005-08-10 |
卫材株式会社 |
用作医药品的大环化合物
|
|
CA2481304A1
(en)
|
2002-03-27 |
2003-10-09 |
Patrick Hwu |
Method for treating cancer in humans
|
|
US7939641B2
(en)
|
2002-04-09 |
2011-05-10 |
The Scripps Research Institute |
Motif-grafted hybrid polypeptides and uses thereof
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
EP2258363A1
(en)
|
2002-05-17 |
2010-12-08 |
Celgene Corporation |
Compositions for treatment of cancers
|
|
CA2752124A1
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
|
|
US7632496B2
(en)
|
2002-07-01 |
2009-12-15 |
Wilex Ag |
Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
|
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
AU2003254641A1
(en)
|
2002-08-28 |
2004-03-19 |
Maxygen Aps |
Interferon beta-like molecules for treatment of cancer
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
AU2003267700A1
(en)
|
2002-09-09 |
2004-03-29 |
Nautilus Biotech |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20040121971A1
(en)
|
2002-12-20 |
2004-06-24 |
Gang Chen |
Therapeutic use of tumor necrosis factor-alpha mutein
|
|
EP1575615A1
(en)
|
2002-12-23 |
2005-09-21 |
Innate Pharma |
Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
|
WO2004080445A1
(en)
|
2003-03-12 |
2004-09-23 |
Molecular Engines Laboratories Sa |
Methods and compositions for the treatment of cancer
|
|
US20070243159A1
(en)
|
2003-04-30 |
2007-10-18 |
Periasamy Selvaraj |
Therapeutic Compositions and Vaccines By Glycosyl-Phosphatidylinositol (Gpi)-Anchored Cytokines and Immunostimulatory Molecules
|
|
EP1643971A2
(en)
|
2003-05-22 |
2006-04-12 |
Neopharm, Inc. |
Liposomal formulations comprising a combination of two or more active agents
|
|
WO2004108078A2
(en)
|
2003-06-02 |
2004-12-16 |
Alexion Pharmaceuticals Inc. |
Rationally designed antibodies
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
CN101120083B
(zh)
|
2003-10-08 |
2013-03-27 |
威尔森沃尔夫制造公司 |
利用透气性材料进行细胞培养的方法及装置
|
|
KR101128777B1
(ko)
|
2003-11-04 |
2012-04-13 |
조마 테크놀로지 리미티드 |
다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
|
|
WO2005084179A2
(en)
|
2003-12-01 |
2005-09-15 |
Immunomedics, Inc. |
Improved method for preparing conjugates of proteins and chelating agents
|
|
ES2305886T3
(es)
|
2003-12-30 |
2008-11-01 |
Merck Patent Gmbh |
Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
|
|
BRPI0506883A
(pt)
|
2004-01-16 |
2007-05-29 |
Univ Michigan |
miméticos de smac conformacionalmente comprimidos e seus usos
|
|
EP1715882A4
(en)
|
2004-01-16 |
2009-04-08 |
Univ Michigan |
SMAC-PEPTIDOMIMETIKA AND ITS USES
|
|
EP1761561B1
(en)
|
2004-01-20 |
2015-08-26 |
KaloBios Pharmaceuticals, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
|
US20050228007A1
(en)
|
2004-02-26 |
2005-10-13 |
Prakash Jagtap |
Isoquinoline derivatives and methods of use thereof
|
|
AU2005228950B2
(en)
|
2004-03-23 |
2012-02-02 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
|
DK2253614T3
(da)
|
2004-04-07 |
2013-01-07 |
Novartis Ag |
IAP-inhibitorer
|
|
KR100984459B1
(ko)
|
2004-07-02 |
2010-09-29 |
제넨테크, 인크. |
Ｉａｐ의 억제제
|
|
WO2006010118A2
(en)
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
|
CA2573644A1
(en)
|
2004-07-12 |
2006-02-16 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
|
ES2475207T3
(es)
|
2004-07-15 |
2014-07-10 |
Tetralogic Pharmaceuticals Corporation |
Compuestos de unión a IAP
|
|
CN1721533A
(zh)
|
2004-07-16 |
2006-01-18 |
中国科学院沈阳应用生态研究所 |
Il2与抗gd2单链抗体融合蛋白及编码基因和应用
|
|
JP2008522951A
(ja)
|
2004-07-19 |
2008-07-03 |
ベイラー・カレツジ・オブ・メデイシン |
サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
|
|
JP2008510829A
(ja)
|
2004-08-25 |
2008-04-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
デンドリマーに基づく組成物およびそれらの使用法
|
|
EP1640018A1
(en)
|
2004-09-24 |
2006-03-29 |
Universität Zürich |
Combinational therapy for treating cancer
|
|
DK1810026T3
(en)
|
2004-10-06 |
2018-07-16 |
Mayo Found Medical Education & Res |
B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
|
|
WO2006050166A2
(en)
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
|
CU23297A1
(es)
|
2004-11-16 |
2008-07-24 |
Ct De Inmunologa A Molecular |
Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
|
|
PT2343380T
(pt)
|
2004-11-16 |
2019-09-18 |
Humanigen Inc |
Permuta de cassetes da região variável de imunoglobulina
|
|
RU2437893C2
(ru)
|
2004-12-09 |
2011-12-27 |
Мерк Патент Гмбх |
Варианты il-7 со сниженной иммуногенностью
|
|
DK1836201T4
(da)
|
2004-12-20 |
2013-11-11 |
Genentech Inc |
Pyrrolidininhibitorer af IAP.
|
|
JP2008528621A
(ja)
|
2005-01-27 |
2008-07-31 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
腎細胞ガンを処置するための方法
|
|
ATE367167T1
(de)
|
2005-02-07 |
2007-08-15 |
Novartis Vaccines & Diagnostic |
Aufbereitung von aldesleukin zur pharmazeutischen verwendung
|
|
MX2007010037A
(es)
|
2005-02-18 |
2008-02-15 |
Novartis Vaccines & Diagnostic |
Agentes antiangiogenicos con aldesleucina.
|
|
JP2008529556A
(ja)
|
2005-02-18 |
2008-08-07 |
メダレックス， インク． |
前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
|
|
WO2006093677A1
(en)
|
2005-02-25 |
2006-09-08 |
Inotek Pharmaceuticals Corporation |
Tetracyclic sulfonamide compounds and methods of use thereof
|
|
MX2007010335A
(es)
|
2005-02-25 |
2007-11-06 |
Inotek Pharmaceuticals Corp |
Compuestos de isoquinolina y metodos de uso de los mismos.
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
CN101180061A
(zh)
|
2005-05-19 |
2008-05-14 |
普罗米蒂克生物科学公司 |
化合物、含有此类化合物的组合物、和治疗转移性黑素瘤和其它癌症的方法
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
DK1912677T3
(da)
|
2005-06-20 |
2014-01-13 |
Psma Dev Company L L C |
PSMA-antistof-lægemiddel-konjugater
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
CA2618218C
(en)
|
2005-07-21 |
2015-06-30 |
Ardea Biosciences, Inc. |
N-(arylamino)-sulfonamide inhibitors of mek
|
|
KR101772375B1
(ko)
|
2005-09-07 |
2017-08-29 |
신라젠(주) |
Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
|
|
KR20080063790A
(ko)
|
2005-09-26 |
2008-07-07 |
노바세아, 인크. |
활성 비타민 ｄ 화합물을 이용하는 화학 요법 또는 방사선요법과 관련된 위장 및 방광 장애의 예방 및 치료
|
|
WO2007051119A1
(en)
|
2005-10-26 |
2007-05-03 |
Mgi Gp, Inc. |
Methods and compositions of parp inhibitors as potentiators in cancer therapy
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
CA2643337C
(en)
|
2006-03-01 |
2016-01-12 |
Janssen Pharmaceutica N.V. |
Cancer treatment combining lymphodepleting agent with ctls and cytokines
|
|
AU2007271398B2
(en)
|
2006-07-06 |
2013-06-20 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
|
|
US8119772B2
(en)
|
2006-09-29 |
2012-02-21 |
California Institute Of Technology |
MART-1 T cell receptors
|
|
WO2008051220A1
(en)
|
2006-10-24 |
2008-05-02 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Interaction of il-27 and il-2 for treatment of tumors
|
|
CA2679268A1
(en)
|
2007-03-09 |
2008-09-18 |
Novartis Ag |
Treatment of melanoma
|
|
WO2008112563A1
(en)
|
2007-03-09 |
2008-09-18 |
Flowmedica, Inc. |
Acute kidney injury treatment systems and methods
|
|
AU2008226337B2
(en)
|
2007-03-14 |
2012-02-16 |
BioLingus IP II GmbH |
Method for treating cancer via the mucosal administration of interleukin
|
|
WO2008134679A1
(en)
|
2007-04-30 |
2008-11-06 |
Genentech, Inc. |
Inhibitors of iap
|
|
EP2150258A2
(en)
|
2007-06-01 |
2010-02-10 |
Innate Pharma S.A. |
Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EP2205242B1
(en)
|
2007-09-12 |
2015-04-15 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
ES2504690T3
(es)
|
2007-10-03 |
2014-10-08 |
Eisai Inc. |
Compuestos inhibidores de PARP, composiciones y métodos de uso
|
|
EP2050458A1
(en)
|
2007-10-17 |
2009-04-22 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL24 for inducing hyperproliferative or autoimmune cell death
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
|
US20140127200A1
(en)
|
2008-01-03 |
2014-05-08 |
The Scripps Research Institute |
Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
|
|
KR101658247B1
(ko)
|
2008-01-03 |
2016-09-22 |
더 스크립스 리서치 인스티튜트 |
모듈 인식 도메인을 통한 항체 표적화
|
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
|
CN101970499B
(zh)
|
2008-02-11 |
2014-12-31 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2009152610A1
(en)
|
2008-06-20 |
2009-12-23 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
GB0815216D0
(en)
|
2008-08-21 |
2008-09-24 |
Asterion Ltd |
Interleukin
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
US8778608B2
(en)
|
2008-10-08 |
2014-07-15 |
The Regents Of The University Of California |
CA9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma
|
|
DK2385763T3
(en)
|
2009-01-12 |
2018-07-16 |
Aerpio Therapeutics Inc |
METHODS OF TREATING VASCULAR LEAK SYNDROME
|
|
JP2012518408A
(ja)
|
2009-02-24 |
2012-08-16 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体
|
|
CA3017298C
(en)
|
2009-05-15 |
2021-09-28 |
Irx Therapeutics, Inc. |
Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
|
|
US9005575B2
(en)
|
2009-06-12 |
2015-04-14 |
Stc.Unm |
Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
|
|
JP5764127B2
(ja)
|
2009-08-17 |
2015-08-12 |
ロシュ グリクアート アーゲー |
標的化イムノコンジュゲート
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
WO2011031865A1
(en)
|
2009-09-09 |
2011-03-17 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
WO2011066521A2
(en)
|
2009-11-30 |
2011-06-03 |
Stc. Unm |
Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
EP2510086A4
(en)
|
2009-12-08 |
2013-05-22 |
Wolf Wilson Mfg Corp |
IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
WO2011090492A1
(en)
|
2010-01-19 |
2011-07-28 |
Immunomedics, Inc. |
Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
|
|
WO2011139738A2
(en)
|
2010-04-28 |
2011-11-10 |
Tenx Biopharma, Inc. |
Therapies using zanolimumab to enhance the immune response
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
WO2012021609A2
(en)
|
2010-08-12 |
2012-02-16 |
Ulrik Mouritzen |
Neoadjuvant treatment of cancer with proleukin
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|
|
US20120201750A1
(en)
|
2010-09-20 |
2012-08-09 |
Bungwoo Ryu |
Serum biomarkers for melanoma metastasis
|
|
WO2012045334A1
(en)
|
2010-10-05 |
2012-04-12 |
Synthon Bv |
Biologically active il-10 fusion proteins
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
SG192673A1
(en)
*
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
KR20130118941A
(ko)
|
2011-02-10 |
2013-10-30 |
로슈 글리카트 아게 |
면역치료법
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
WO2013044169A1
(en)
|
2011-09-21 |
2013-03-28 |
Nestec S.A. |
Methods for determining combination therapy with il-2 for the treatment of cancer
|
|
CA2849033C
(en)
|
2011-09-26 |
2020-05-05 |
Philogen S.P.A. |
Immunocytokine combination therapy
|
|
WO2013056240A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
|
PL2768939T3
(pl)
|
2011-10-21 |
2017-02-28 |
Cell Medica Limited |
Urządzenie do aseptycznego rozwoju komórek
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
CA2863224A1
(en)
*
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
|
WO2013116781A1
(en)
|
2012-02-02 |
2013-08-08 |
Acceleron Pharma Inc. |
Alk1 antagonists and their uses in treating renal cell carcinoma
|
|
JP6639228B2
(ja)
|
2012-03-29 |
2020-02-05 |
アルター・バイオサイエンス・コーポレーション |
新生物を治療するための方法
|
|
AU2013260132B2
(en)
|
2012-05-08 |
2017-12-14 |
The Johns Hopkins University |
Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
|
|
EP2850175B1
(en)
|
2012-05-18 |
2020-12-16 |
Wilson Wolf Manufacturing Corporation |
Improved methods of cell culture for adoptive cell therapy
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
EP2859093A4
(en)
|
2012-06-11 |
2016-08-17 |
Wolf Wilson Mfg Corp |
IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
|
|
MY175687A
(en)
|
2012-08-07 |
2020-07-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
PE20150645A1
(es)
|
2012-08-08 |
2015-05-11 |
Roche Glycart Ag |
Proteinas de fusion de interleuquina 10 y usos de las mismas
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
WO2014078272A1
(en)
|
2012-11-13 |
2014-05-22 |
Mayo Foundation For Medical Education And Research |
Methods and materials for assessing immune system profiles
|
|
EP2943512A4
(en)
|
2013-01-11 |
2016-06-01 |
California Inst Biomedical Res |
BOVINE FUSION ANTIBODY
|
|
EP2961415B1
(en)
|
2013-03-01 |
2021-01-06 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
EP3628322A1
(en)
|
2013-03-01 |
2020-04-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
|
|
CN105358678A
(zh)
|
2013-03-08 |
2016-02-24 |
密苏里大学董事会 |
治疗和/或预防1型糖尿病的方法和组合物
|
|
WO2014152122A2
(en)
|
2013-03-15 |
2014-09-25 |
Children's Medical Center Corporation |
Methods of altering vascular permeability and uses thereof
|
|
US20150017120A1
(en)
|
2013-06-13 |
2015-01-15 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
|
|
CN118562610A
(zh)
|
2013-06-24 |
2024-08-30 |
威尔逊沃夫制造公司 |
用于透气性细胞培养过程的封闭系统装置和方法
|
|
WO2015006744A1
(en)
|
2013-07-11 |
2015-01-15 |
The California Institute For Biomedical Research |
Immunoglobulin fusion proteins and compositions thereof
|
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
|
US9572828B2
(en)
|
2013-07-18 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
US10233425B2
(en)
|
2013-09-16 |
2019-03-19 |
The Trustees Of The University Of Pennsylvania |
CD137 enrichment for efficient tumor infiltrating lymphocyte selection
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
WO2015117930A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
EP3113793B1
(en)
|
2014-03-06 |
2020-11-18 |
Morphogenesis, Inc. |
Dna vector and transformed tumor cell vaccines
|
|
US20170216401A1
(en)
|
2014-03-17 |
2017-08-03 |
Piotr Jachimczak |
Combination for use in a method of treating cancer
|
|
ES2900262T3
(es)
|
2014-03-17 |
2022-03-16 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch Inst Vertreten Durch Seinen Praeside |
Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular
|
|
AU2015231041B2
(en)
|
2014-03-20 |
2020-07-16 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
WO2015157636A1
(en)
|
2014-04-10 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
RU2739770C2
(ru)
|
2014-06-11 |
2020-12-28 |
полибайосепт ГмбХ |
Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
|
|
CA2957717C
(en)
*
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
AU2014407539B2
(en)
|
2014-10-02 |
2020-10-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
|
GB201419976D0
(en)
|
2014-11-10 |
2014-12-24 |
Univ Newcastle |
Biomarkers for disease progression in melanoma
|
|
EP3034092A1
(en)
|
2014-12-17 |
2016-06-22 |
Université de Lausanne |
Adoptive immunotherapy for treating cancer
|
|
RU2018124307A
(ru)
*
|
2015-12-04 |
2020-01-14 |
Новартис Аг |
Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
|
|
JP7308505B2
(ja)
|
2016-01-08 |
2023-07-14 |
マキシオン セラピューティクス リミテッド |
多様性を変化させた足場ドメインを有する結合メンバー
|
|
HUE066460T2
(hu)
|
2016-10-26 |
2024-08-28 |
Iovance Biotherapeutics Inc |
A kriokonzervált tumor infiltráló limfociták restimulációja
|
|
MY206158A
(en)
*
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|